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  Purpose: The aim of this study was to evaluate the be-
havior of endometrial stromal sarcomas (ESSs) in rela -
tion to their clinical and pathogenic features, and to de-
termine the optimal treatment strategy.
  Materials and Methods:  A retrospective analysis was 
performed involving 28 patients with histologic-proven 
ESSs treated at our institution between 1987 and 2006.
  Results: The median follow-up was 54.7±63.1 months
and the 5-year survival rate was 82.0%. Twenty-two 
(81.5%) and 5 patients (18.5%) had low- and high-grade  
disease, respectively. Univariate analysis revealed that 
the histologic grades, based on mitotic count, were asso-
ciated with longer survival (p=0.004). However, among 
those patients with low-grade tumors, 5/20 patients 
(25%) had a recurrence and 2/21 patients (9.5%) had 
distant metastasis during the follow-up period. With the  
exception of 2 patients, 26 patients with ESSs underwent 
hysterectomy as primary treatment. Adjuvant treatment 
after surgery was administered to 14/26 patients (53.8%).
Hormone therapy with progesterone, chemotherapy, 
and/or radiotherapy did not influence overall survival. 
However, the postoperative adjuvant therapy group, re-
gardless of the treatment modality, was associated with 
relatively increased overall survival when compared to 
the surgery only group (p=0.054).
  Conclusion: The preoperative differential diagnosis of 
ESSs from other benign gynecologic diseases is often 
difficult. We recommend adjuvant therapy be ad-
ministered after hysterectomy in patients with ESS to pre -
vent recurrence or distant metastasis. (Cancer Res Treat. 
2008;40:6-10)
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INTRODUCTION
  Endometrial stromal sarcomas (ESSs) are very rare, malig-
nant uterine tumors, comprising ＜1% of all uterine cancers (1). 
Frequently, ESSs are detected by chance at the time of 
diagnostic dilatation and curettage (D&C), myomectomy, or 
hysterectomy for presumed benign uterine disease. Because of 
the non-specific characteristics of ESSs, little is known regar-
ding the pathogenesis, risk factors, optimal therapy, or out-
comes.
  The following characteristics have been shown to have 
prognostic significance for ESSs: tumor size, FIGO stage, 
grade, age, and menopausal status (2). The most reliable known 
prognostic factors are the grade of tumor and the extent of 
disease (3). ESSs can be divided into low- and high-grade ESSs 
based on a mitotic count of less or more than 10 mitoses/10 
high power fields and characterized by a proliferation cells with 
endometrial stromal differentiation (4). Low-grade ESS has an 
indolent clinical course, whereas high-grade ESS behaves in a 
more aggressive manner with a poorer overall prognosis. 
Accordingly, it has been suggested that high-grade ESS should 
be regarded as a different disease entity altogether (5). 
However, some authors are of the opinion that mitotic count is 
not indicative of tumor recurrence or tumor-related deaths (6).
  The fundamental treatment for ESSs consists of total 
hysterectomy with bilateral salpingo-oophorectomy. However, 
Li et al(7) recently demonstrated that ovarian preservation 
could be a safe option for surgical treatment in stage I, 
low-grade ESS. The importance of surgical staging, including 
lymphadenectomy, is still unknown (3). Due to the high 
recurrence risk, even with localized tumors, many clinicians 
advocate the use of adjuvant therapy (2); however, no 
prospective studies have been conducted regarding the merits 
of adjuvant radiation and/or chemotherapy or hormonal 
treatment. Of note, the overall survival does not appear to 
improve with adjuvant therapy (8,9).
  The aim of this study was to evaluate the behavior of ESSs 
in relation to its clinical and pathogenic features and to 
determine the optimal treatment strategy.
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Fig. 1. Low-grade ESS. The tumor resembles normal stroma of proliferative endometrium, characterized by generally uniform cells with 
minimal nuclear pleomorphism and cytologic atypia, hyalinized connective tissue, and a rich, vascularized background (left, hematoxylin 
and eosin; right, corresponding part of the left slide stained positive for CD10).
Fig. 2. High-grade ESS. The tumor is composed of anaplastic spindle cells that have a high mitotic index and frequently encountered 
abnormal mitotic figures. (left, hematoxylin and eosin; right, corresponding part of the left slide stained negative for CD10).
MATERIALS AND METHODS
  This study included 28 patients with histologic-proven ESS 
treated between 1987 and 2006 in the Department of Obstetrics 
and Gynecology of Yonsei University College of Medicine. 
Data were retrospectively reviewed and included age at the time 
of diagnosis, patient demographics, clinical presentation, extent 
of surgery performed, adjuvant therapy, patient outcome, 
recurrence patterns, and follow-up status.
  Twenty-two cases of low-grade ESS and 5 cases of high- 
grade ESS were identified. One case was not classified as either 
low- or high-grade ESS due to diagnostic ambiguity. Surgical 
staging was based retrospectively on the 1988 FIGO guidelines 
for cancer of the uterine corpus (10). Total hysterectomy and 
removal of as much tumor as possible was performed as a 
surgical procedures. With respect to the patients who made up 
the current study, the decision to perform adjuvant therapy was 
left to the individual physician, thus the adjuvant and 
non-adjuvant groups were not necessarily similar. The adjuvant 
group was administered chemotherapy, radiotherapy, or hormonal 
therapy. Some patients had a combination of the therapies. 
Megestrol acetate (120∼320 mg/day for 6∼12 months) was 
used as hormonal therapy. Chemotherapeutic regimens were 
variable; however, mainly consisted of a combination of 
ifosfamide, adriamycin, and platinum based-agents.
  Survival analysis was used to compare patients with or 
without specific clinicopathologic parameters in terms of pro-
gression-free and overall survival. The Kaplan-Meier method 
was used to estimate survival curves, and the log-rank statistic 
was used to test the equality of the survival functions between 
the patients with or without specific clinicopathologic para-
meters.
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Fig. 3. Overall survival as a function of ESS grade.
Fig. 4. Overall survival based on adjuvant therapy after surgical 
treatment.
Table 1. Patient characteristics
Characteristics Patients (n=28)
  Age Median    47
Range  20∼76
  Stage I 16 (57.1%)
III  4 (14.3%)
IV  3 (10.7%)
Unknown  5 (17.9%)
  Grade Low 22 (78.6%)
High  5 (17.9%)
Unknown  1 (3.6%)
  Distant metastasis No 22 (78.6%)
Yes  5 (17.9%)
Unknown  1 (3.6%)
  Hysterectomy Yes 26 (92.9%)
No  2 (7.1%)
Table 2. Adjuvant therapy after surgical treatment (n=26)
Low-grade ESS High-grade ESS
(n=21) (n=5)
Observation  9 (42.9%) 3 (60.0%)
RTx* 2 (9.5%) 0
CTx†  3 (14.3%) 0
HTx‡  5 (23.8%) 0
RTx+CTx 1 (4.8%)  1 (20.0%)
RTx+HTx 1 (4.8%) 0
RTx+CTx+HTx 0  1 (20.0%)
*radiotherapy, †chemotherapy, ‡hormonal treatment.
Table 3. Clinical outcomes of patients
Low-grade ESS High-grade ESSOutcomes (n=22) (n=5)
No evidence of disease 15 (68.1%) 1 (20.0%)
Alive with disease  4 (18.2%) 0
Dead of disease 1 (4.5%) 2 (40.0%)
Missing 2 (9.1%) 2 (40.0%)
RESULTS
  The median age at the time of diagnosis was 47.0 years 
(range, 20∼76 years). Sixteen patients (57.1%) were referred 
to our institution from private clinics for definitive treatment 
of ESSs. They had previously undergone either hysterectomy, 
myomectomy, D&C, or hysteroscopy for presumed benign 
gynecologic conditions. Experienced pathologists analyzed all 
specimens (Fig. 1, 2). Patient characteristics are listed in Table 1.
  Twenty-six of 28 patients had undergone total hysterectomy 
with or without bilateral salpingo-oophorectomy as part of their 
initial surgical treatment. Two patients had radiotherapy for 
their initial treatment. More than one-half of the patients (16/26 
[61.5%]) were stage I. Distant metastasis outside the pelvis at 
the time of diagnosis had occurred in 5 patients (17.9%); 
para-aortic lymph node metastasis occurred in 1 patient each 
from the low- and high-grade ESS. Also, one patient with a 
high-grade ESS had metastasis to the omentum, and 2 patients 
with low-grade ESSs had metastasis to the bladder and lung 
(i.e., stage IV), respectively.
  Adjuvant therapy after surgery was performed in 14/26 cases 
(53.8%; Table 2). The most common choice for adjuvant 
therapy in low-grade ESSs was hormonal treatment with mege-
strol acetate. In 5 patients with high-grade ESSs, 2 patients 
were treated with radiation therapy in combination with 
chemotherapy as adjuvant treatment. One of the patients also 
had hormonal treatment with megestrol acetate (480 mg/day). 
One patient with a high-grade ESS voluntarily discontinued 
adjuvant treatment because of her advanced age, and the other 
2 patients voluntarily discontinued treatment due to poor 
performance status with extensive disease.
  The median overall survival was 56.5 months [95% CI: 47.0
∼97.6] and the 5-year survival rate was 82.0%. Five patients 
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(22.7%) with low-grade ESSs developed disease recurrence, 
one of whom died from the disease (Table 3). However, only 
1 patient (20.0%) with a high-grade ESS showed no evidence 
of disease in a recent follow-up visit. Three patients with 
recurrent, low-grade ESS had intra-abdominal recurrent disease 
a few years after the initial diagnosis of their disease, while 
1 patient had lung metastasis 13 years after diagnosis; the other 
patient had metastasis to the abdominal wall 12 years after the 
initial diagnosis.
  Univariate analysis revealed that the histologic grade 
according to the mitotic count was associated with longer 
survival (p=0.004; Fig. 3). Other potential prognostic factors, 
such as stage, existence of lymph node metastasis, and age did 
not influence either disease-free survival or overall survival. 
Postoperative adjuvant therapy, hormone therapy, chemotherapy, 
and/or radiotherapy did not individually influence overall 
survival. However, the postoperative adjuvant therapy group, 
regardless of the treatment modality, was associated with 
relatively increased overall survival when compared to the no 
adjuvant therapy group (p=0.054; Fig. 4).
DISCUSSION
  ESS is a tumor arising from the cells of the endometrial 
stroma. It can originate from the endometrium, adenomyosis, 
and occasionally, endometriosis. Because of the rarity of ESS, 
only small numbers of retrospective studies exist regarding the 
early diagnosis, prognostic factors, tumor behavior, and 
treatment guidelines.
  Due to the great similarity of ESS with normal endometrium, 
it may be impossible to diagnose low-grade ESS with certainty 
on curettage fragments, and the definitive diagnosis can be 
made only on a hysterectomy specimen (11). Only 5 patients 
were diagnosed with malignancy in our series by D&C. 
Imaging studies, such as magnetic resonance imaging or 
sonography, have only a limited role in the diagnosis of ESS 
from endometrial cancer, uterine myoma, or adenomyosis 
(12,13). In the current study, 16/28 (57.1%) patients were 
referred from local clinics after hysterectomy, myomectomy, 
D&C, or hysteroscopy for presumed benign gynecologic con-
ditions (57.1%). A recent study reported that optimal cytore-
ductive surgery could improve the median survival of patients 
with ESSs (14). Appropriate diagnostic modalities would 
therefore lead to a reduction in the rate of re-operations.
  Optimized therapeutic guidelines have not been agreed upon. 
Surgery has always been described as the most effective 
treatment for uterine sarcomas (2,15). However, the extent of 
surgery, especially the role of lymphadenectomy, is contro-
versial. When patients are referred to our institute after hystere-
ctomy, they usually undergo radiation therapy as a primary 
treatment, whereas when referred after D&C or myomectomy, 
patients typically undergo surgical staging, including lymph-
adenectomy. One study patient who underwent lymphadectomy 
for low-grade ESS had lymph node metastasis in the para-aortic 
area. In agreement with our study, recent data suggests that the 
rate of lymph node involvement in low-grade ESSs may be 
higher than expected (16). However, the therapeutic benefit of 
radical lymphadenectomy is still uncertain. 
  Consistent with previous reports, the grade of tumor was the 
most significant prognostic factor in our study. Patients with 
low-grade ESSs had better survival compared to those patients 
with high-grade ESSs (3,14,17). However, patients with 
low-grade ESSs are frequently diagnosed in an early tumor 
stage, but still experience late recurrence or metastasis. Five 
patients (22.7%) with low-grade ESSs developed disease 
recurrence, one of whom died of disease in our series. There-
fore, this could be the rationale for adjuvant therapy to prevent 
late recurrence or metastasis. 
  Adjuvant therapy for patients with ESSs is still controversial 
(17). One study reported no difference in the recurrence rate 
in patients who had surgery with adjuvant therapy versus 
surgery alone (8). However, with respect to the presumed need 
to treat those patients perceived to be at higher risk with 
adjuvant therapy, the current study showed that the 
postoperative adjuvant therapy group regardless of the treatment 
modality was associated with relatively increased overall 
survival when compared to no adjuvant therapy group (p= 
0.054). Therefore, strong consideration should be given to 
performing adjuvant therapy, even in patients with low-grade 
ESSs. Unfortunately, the optimal choice of adjuvant therapy for 
ESSs is unknown, with options including radiation therapy, 
chemotherapy, and hormonal therapy either alone or in varying 
combinations.
  Chemotherapeutic regimens utilized to treat ESS have 
included both single and combination agent therapy, including 
ifosfamide, cyclophosphamide, doxorubicin, adriamycin, cisplatin, 
etoposide, parclitaxel, and carboplatin (15,18∼21). Non- 
randomized studies have described a favorable response with 
doxorubicin-based chemotherapy (8). Randomized controlled 
trials have suggested that the most effective single agent 
appears to be ifosfamide, with a 33% response rate (a 14% 
complete response and a 19% partial response) in a phase II 
trial by the Gynecologic Oncology Group for recurrent or 
metastatic disease (18).
  Similar to chemotherapy, no definite recommendations exist 
for adjuvant hormone therapy in patients, especially with 
low-grade ESS. Several reports have been published on the 
efficacy of progestin (4,22) and aromatase inhibitors in the 
treatment of metastatic ESS (23). One advantage of adjuvant 
hormone therapy is that it allows long-term maintenance 
therapy. In addition, it appears that women with advanced stage 
disease benefit from adjuvant hormone therapy (24).
  A combination of surgery and adjuvant radiotherapy may 
improve the treatment outcome compared to surgery alone (25). 
However, Gadducci et al. showed no big difference in the 
outcome of patients with low-grade ESSs treated by surgery 
alone and surgery with adjuvant radiotherapy (3). For more 
convincing results, prospective studies with larger case series 
are necessary to help define the optimal choice of treatment.
  Taken together, we have shown that clinical outcomes can 
be readily depicted based on the grade of the ESS. Also, we 
recommend adjuvant therapy to be performed after hysterec-
tomy to prevent recurrence or distant metastasis, even in low- 
grade ESSs.
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CONCLUSION
  The differential diagnosis of ESSs from other benign 
gynecologic diseases before surgery is often difficult. Though 
it is known that grade is the most important prognostic factor 
for patients with ESSs, recurrence or distant metastasis are not 
rare in low-grade tumors. Accordingly, it is advised that adju-
vant therapy be performed after hysterectomy to prevent 
recurrence or distant metastasis.
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